Target: CAIX

Indicant: renal cancer

MOA & Molecule Type: Peptide Receptor Radionuclide Therapy

Development stage: R&D

Summary: CAIX is a protein expressed on the surface of cancer cells and is a biomarker related to cancer stem cells that play an absolute role in cancer cell survival by controlling pH around cancer cells and maintaining the growth and metastasis of cancer cells.
CBT-001 is a radioactive diagnostic and therapeutic agent made by combining peptides that selectively bind to CAIX developed by our company and radioisotopes.
Compared to the current competitor, it was confirmed that it strongly binds to cancer cells and maintains a high concentration for a long time to maximize the therapeutic effect, and the non-bound substances are quickly metabolized and the toxicity to normal cells is minimized.
In addition, CAIX protein is highly interested in pharmaceutical companies, but it is expected to become First in class because there is no approved treatment for the protein so far.